CA3095297A1 - Methods of treating ulcerative colitis - Google Patents
Methods of treating ulcerative colitis Download PDFInfo
- Publication number
- CA3095297A1 CA3095297A1 CA3095297A CA3095297A CA3095297A1 CA 3095297 A1 CA3095297 A1 CA 3095297A1 CA 3095297 A CA3095297 A CA 3095297A CA 3095297 A CA3095297 A CA 3095297A CA 3095297 A1 CA3095297 A1 CA 3095297A1
- Authority
- CA
- Canada
- Prior art keywords
- administered
- dose
- antibody
- mirikizumab
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650314P | 2018-03-30 | 2018-03-30 | |
| US62/650,314 | 2018-03-30 | ||
| PCT/US2019/024633 WO2019191464A1 (en) | 2018-03-30 | 2019-03-28 | Methods of treating ulcerative colitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3095297A1 true CA3095297A1 (en) | 2019-10-03 |
Family
ID=66429483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3095297A Pending CA3095297A1 (en) | 2018-03-30 | 2019-03-28 | Methods of treating ulcerative colitis |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12152072B2 (https=) |
| EP (2) | EP4327866B1 (https=) |
| JP (4) | JP7119114B2 (https=) |
| KR (1) | KR102552693B1 (https=) |
| CN (1) | CN111936165A (https=) |
| AU (2) | AU2019243283C1 (https=) |
| BR (1) | BR112020018099A2 (https=) |
| CA (1) | CA3095297A1 (https=) |
| DK (2) | DK3773715T3 (https=) |
| EA (1) | EA202091989A1 (https=) |
| ES (2) | ES3063700T3 (https=) |
| FI (2) | FI4327866T3 (https=) |
| HR (2) | HRP20260275T1 (https=) |
| HU (1) | HUE067445T2 (https=) |
| IL (2) | IL277514B2 (https=) |
| LT (2) | LT3773715T (https=) |
| MA (2) | MA52216B1 (https=) |
| MD (2) | MD4327866T2 (https=) |
| MX (1) | MX2020010269A (https=) |
| MY (1) | MY202368A (https=) |
| PL (2) | PL4327866T3 (https=) |
| PT (2) | PT4327866T (https=) |
| RS (2) | RS67806B1 (https=) |
| SG (1) | SG11202009526RA (https=) |
| SI (2) | SI3773715T1 (https=) |
| TW (2) | TWI744617B (https=) |
| UA (1) | UA128578C2 (https=) |
| WO (1) | WO2019191464A1 (https=) |
| ZA (1) | ZA202005388B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7805788B2 (ja) | 2019-05-23 | 2026-01-26 | ヤンセン バイオテツク，インコーポレーテツド | Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 |
| BR112022015996A2 (pt) * | 2020-02-14 | 2022-10-11 | Janssen Biotech Inc | Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23 |
| IL298389A (en) | 2020-05-21 | 2023-01-01 | Janssen Biotech Inc | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| JP7423815B2 (ja) * | 2020-10-20 | 2024-01-29 | セトラスホールディングス株式会社 | 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム |
| TW202241506A (zh) * | 2021-01-06 | 2022-11-01 | 美商艾伯維有限公司 | 治療克羅恩氏病及潰瘍性結腸炎之方法 |
| BR112023024064A2 (pt) * | 2021-05-20 | 2024-01-30 | Janssen Biotech Inc | Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa |
| JP2024521748A (ja) * | 2021-05-28 | 2024-06-04 | イーライ リリー アンド カンパニー | 潰瘍性大腸炎に関与する遺伝子の抗ｉｌ－２３ｐ１９抗体調節 |
| US20230159633A1 (en) * | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
| AU2023383916A1 (en) * | 2022-11-22 | 2025-07-10 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
| TW202500184A (zh) | 2023-03-10 | 2025-01-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
| CN121443635A (zh) * | 2023-06-16 | 2026-01-30 | 信达生物医药科技(杭州)有限公司 | 重组抗白介素23p19亚基抗体在治疗炎症性肠病中的用途 |
| WO2025170982A2 (en) | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2026060205A1 (en) | 2024-09-13 | 2026-03-19 | Eli Lilly And Company | PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2452694T1 (sl) * | 2005-06-30 | 2019-05-31 | Janssen Biotech, Inc. | Protitelesa proti-IL-23, sestavki in postopki uporabe |
| HUE034269T2 (en) | 2005-12-29 | 2018-02-28 | Janssen Biotech Inc | Human anti-IL-23 antibodies, preparations, methods and applications |
| ES2708988T3 (es) | 2007-02-23 | 2019-04-12 | Merck Sharp & Dohme | Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética |
| JP2012507723A (ja) * | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| MX2019000046A (es) * | 2010-11-04 | 2023-10-05 | Boehringer Ingelheim Int | Anticuerpos anti-il-23. |
| AR094877A1 (es) | 2013-03-08 | 2015-09-02 | Lilly Co Eli | Anticuerpos que se unen a il-23 |
| US20170002060A1 (en) * | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
| MX2020009265A (es) * | 2018-03-05 | 2020-10-01 | Janssen Biotech Inc | Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23. |
-
2019
- 2019-03-27 TW TW108110767A patent/TWI744617B/zh active
- 2019-03-27 TW TW110139868A patent/TWI837532B/zh active
- 2019-03-28 ES ES23215626T patent/ES3063700T3/es active Active
- 2019-03-28 RS RS20260242A patent/RS67806B1/sr unknown
- 2019-03-28 ES ES19722256T patent/ES2983809T3/es active Active
- 2019-03-28 CA CA3095297A patent/CA3095297A1/en active Pending
- 2019-03-28 AU AU2019243283A patent/AU2019243283C1/en active Active
- 2019-03-28 PL PL23215626.5T patent/PL4327866T3/pl unknown
- 2019-03-28 BR BR112020018099-8A patent/BR112020018099A2/pt unknown
- 2019-03-28 PT PT232156265T patent/PT4327866T/pt unknown
- 2019-03-28 EA EA202091989A patent/EA202091989A1/ru unknown
- 2019-03-28 LT LTEPPCT/US2019/024633T patent/LT3773715T/lt unknown
- 2019-03-28 HR HRP20260275TT patent/HRP20260275T1/hr unknown
- 2019-03-28 DK DK19722256.5T patent/DK3773715T3/da active
- 2019-03-28 SI SI201930750T patent/SI3773715T1/sl unknown
- 2019-03-28 US US16/981,915 patent/US12152072B2/en active Active
- 2019-03-28 CN CN201980023563.3A patent/CN111936165A/zh active Pending
- 2019-03-28 EP EP23215626.5A patent/EP4327866B1/en active Active
- 2019-03-28 FI FIEP23215626.5T patent/FI4327866T3/fi active
- 2019-03-28 DK DK23215626.5T patent/DK4327866T3/da active
- 2019-03-28 MD MDE20241003T patent/MD4327866T2/ro unknown
- 2019-03-28 FI FIEP19722256.5T patent/FI3773715T3/fi active
- 2019-03-28 WO PCT/US2019/024633 patent/WO2019191464A1/en not_active Ceased
- 2019-03-28 PL PL19722256.5T patent/PL3773715T3/pl unknown
- 2019-03-28 SI SI201931019T patent/SI4327866T1/sl unknown
- 2019-03-28 MA MA52216A patent/MA52216B1/fr unknown
- 2019-03-28 UA UAA202005571A patent/UA128578C2/uk unknown
- 2019-03-28 RS RS20240698A patent/RS65661B1/sr unknown
- 2019-03-28 MD MDE20210135T patent/MD3773715T2/ro unknown
- 2019-03-28 JP JP2020552872A patent/JP7119114B2/ja active Active
- 2019-03-28 IL IL277514A patent/IL277514B2/en unknown
- 2019-03-28 IL IL312807A patent/IL312807B2/en unknown
- 2019-03-28 SG SG11202009526RA patent/SG11202009526RA/en unknown
- 2019-03-28 MA MA67901A patent/MA67901B1/fr unknown
- 2019-03-28 MX MX2020010269A patent/MX2020010269A/es unknown
- 2019-03-28 HU HUE19722256A patent/HUE067445T2/hu unknown
- 2019-03-28 KR KR1020207027982A patent/KR102552693B1/ko active Active
- 2019-03-28 PT PT197222565T patent/PT3773715T/pt unknown
- 2019-03-28 HR HRP20240904TT patent/HRP20240904T1/hr unknown
- 2019-03-28 LT LTEP23215626.5T patent/LT4327866T/lt unknown
- 2019-03-28 MY MYPI2020004942A patent/MY202368A/en unknown
- 2019-03-28 EP EP19722256.5A patent/EP3773715B1/en active Active
-
2020
- 2020-08-28 ZA ZA2020/05388A patent/ZA202005388B/en unknown
-
2022
- 2022-08-03 JP JP2022123689A patent/JP7331219B2/ja active Active
-
2023
- 2023-08-09 JP JP2023130117A patent/JP7571225B2/ja active Active
- 2023-10-11 AU AU2023248103A patent/AU2023248103B2/en active Active
-
2024
- 2024-10-09 JP JP2024176901A patent/JP2025020134A/ja active Pending
- 2024-10-16 US US18/917,597 patent/US20250034243A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023248103B2 (en) | Methods of treating ulcerative colitis | |
| AU2023265759A1 (en) | Mirikizumab for use in a method of treating Crohn's Disease | |
| HK40101440A (en) | Mirikizumab in the treatment of ulcerative colitis | |
| HK40036550A (en) | Mirikizumab in the treatment of ulcerative colitis | |
| HK40036550B (en) | Mirikizumab in the treatment of ulcerative colitis | |
| EA049081B1 (ru) | Способы лечения язвенного колита |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200925 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240826 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241030 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250226 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250226 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250426 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250426 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250811 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260106 |